<DOC>
	<DOCNO>NCT00106353</DOCNO>
	<brief_summary>This open label , two-part study temsirolimus give 60-minute intravenous ( IV ) infusion weekly pediatric subject advance solid tumor . Part 1 ascending-dose study evaluate safety IV temsirolimus give weekly subject age 1 21 year advance solid tumor disease recurrent refractory standard therapy standard therapy available . ( enrollment complete ) Part 2 conduct three group child refractory relapse pediatric solid tumor . Subjects follow tumor type enrol : neuroblastoma , rhabdomyosarcoma , high-grade glioma . Subjects receive IV temsirolimus weekly disease progression unacceptable toxicity . ( recruit )</brief_summary>
	<brief_title>Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Part 1 : Subjects histological diagnosis advance cancer ( solid tumor central nervous system [ CNS ] tumor ) disease recurrent refractory standard therapy standard therapy available ( histological confirmation waive brain stem gliomas optic pathway tumor ) Part 2 : Subjects histologically confirm diagnosis refractory relapse : Neuroblastoma , Highgrade glioma : glioblastoma multiforme , anaplastic astrocytomas , highgrade glioma ( histological confirmation waive brain stem glioma ) , Rhabdomyosarcoma . Measurable disease ( subject neuroblastoma , evaluable disease determine positive metaiodobenzylguanidine ( MIBG ) scan also permit ) . Subjects receive enzymeinducing anticonvulsant . Pulmonary hypertension pneumonitis Active infection serious intercurrent illness Other exclusion apply</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Pediatric Tumors</keyword>
</DOC>